Case Reports
Use of subcutaneous deferoxamine in a child with hemochromatosis associated with congenital dyserythropoietic anemia, type I
- PMID: 7078263
Item in Clipboard
Case Reports
Use of subcutaneous deferoxamine in a child with hemochromatosis associated with congenital dyserythropoietic anemia, type I
Mayo Clin Proc.
1982 May.
Abstract
A 12-year-old girl with congenital dyserythropoietic anemia, type I, was diagnosed as having hemochromatosis. Deferoxamine was given subcutaneously for 14 months. Iron overload, as measured by liver iron and serum ferritin levels, was reduced substantially, liver function tests improved, and hepatomegaly decreased. Toxicity was negligible.
Similar articles
-
Severe hemochromatosis: the predominant clinical manifestation of congenital dyserythropoietic anemia type 2.Acta Haematol. 1985;74(3):178-80. doi: 10.1159/000206205. Acta Haematol. 1985. PMID: 3938164
-
[Successful treatment of congenital dyserythropoietic anemia type I with long-term administration of deferoxamine].Rinsho Ketsueki. 1988 Sep;29(9):1454-9. Rinsho Ketsueki. 1988. PMID: 3063858 Review. Japanese. No abstract available.
-
[Long-term efficacy of subcutaneous administration of deferoxamine in patients with secondary hemochromatosis].Rinsho Ketsueki. 1996 Apr;37(4):303-10. Rinsho Ketsueki. 1996. PMID: 8847800 Japanese.
-
[Congenital dyserythropoietic anemia: types I and II. Study of 2 cases].Sangre (Barc). 1985;30(1):37-46. Sangre (Barc). 1985. PMID: 4002097 Spanish. No abstract available.
-
[Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia].Klin Padiatr. 2010 Nov;222(6):399-406. doi: 10.1055/s-0030-1265178. Epub 2010 Sep 22. Klin Padiatr. 2010. PMID: 20862634 German.
Cited by
-
Congenital diserythropoietic anemia type I. Report on monozygotic twins with associated hemochromatosis and short stature.Blut. 1990 Oct;61(4):248-50. doi: 10.1007/BF01744140. Blut. 1990. PMID: 2224147
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical